Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada
In Quebec, Canada, eligibility for palivizumab (PVZ) immunoprophylaxis was expanded in fall 2016 to include healthy-full-term (HFT) infants residing in the circumpolar region of Nunavik and aged
Auteurs (Zotero)
Gilca, Rodica; Billard, Marie-Noëlle; Zafack, Joseline; Papenburg, Jesse; Boucher, François D.; Charest, Hugues; Rochette, Marie; De Serres, Gaston
